Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-016251
Filing Date
2023-05-01
Accepted
2023-05-01 16:18:14
Documents
17
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A snse-20221231.htm   iXBRL 10-K/A 1039364
2 EX-10.7 snse-ex10_7.htm EX-10 32566
3 EX-31.1 snse-ex31_1.htm EX-31 12330
4 EX-31.2 snse-ex31_2.htm EX-31 11946
  Complete submission text file 0000950170-23-016251.txt   3476436

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT snse-20221231_pre.xml EX-101.PRE 486836
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT snse-20221231_cal.xml EX-101.CAL 62980
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT snse-20221231_def.xml EX-101.DEF 312504
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT snse-20221231.xsd EX-101.SCH 77868
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT snse-20221231_lab.xml EX-101.LAB 641887
11 EXTRACTED XBRL INSTANCE DOCUMENT snse-20221231_htm.xml XML 11691
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39980 | Film No.: 23873931
SIC: 2834 Pharmaceutical Preparations